Key facts
- neurocare’s last known valuation is $75.8M (Jan 2024).
- It has raised $20.0M; the latest was PE Growth/Expansion ($20.0M) in Feb 2025.
- Notable investors include Plutus Investment Group, Additio Investment Group, Aescuvest, Convergence Partners (Switzerland), Impact Expansion — 13 tracked in total.
- Status: Acquired/Merged.
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for neurocare
- ·The full record, as it builds
Funding rounds
No funding rounds for neurocare are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About neurocare
Developer of a digital therapy platform (DTP) designed to empower clinicians to deliver best practices. The company's platform offers fully personalized practice features, factoring in brain activity, sleep, biomarkers and other lifestyle factors and metrics to deliver a completely tailored and individualized program, enabling patients to get a measurable and effective clinical approach that is based on the natural ability to learn about neuroplasticity conveniently.
- Sector
- Healthcare
- HQ
- Munich, Germany
- Founded
- 2014
- Employees
- 200
- Website
- neurocaregroup.com/
- Ownership
- Acquired/Merged
neurocare doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in neurocare shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on neurocare in its N-PORT filings yet. We sweep new filings monthly.